首页> 外国专利> New 4-(alkyl, alkenyl or alkynyl)-cyclohexylamine derivatives, are ORL1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain

New 4-(alkyl, alkenyl or alkynyl)-cyclohexylamine derivatives, are ORL1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain

机译:新的4-(烷基,烯基或炔基)-环己胺衍生物是有用的ORL1受体配体,例如。用于治疗焦虑症,抑郁症,癫痫病,老年性痴呆,戒断症状或特别是疼痛

摘要

1-Substituted 4-(omega -substituted alkyl, alkenyl or alkynyl)-cyclohexylamine derivatives (I) are new. Cyclohexylamine derivatives of formula (I), optionally in the form of racemates, pure stereoisomers (especially enantiomers or diastereomers) or their mixtures in all proportions, including free bases, free acids, salts (specifically acid or base addition salt) or solvates (specifically hydrates), are new. [Image] ----- : optional bond; R 1, R 2H, Alk, Cyc, Ar, Het, -Q 1-Ar, -Q 1-Cyc' or -Q 1-Het; or NR 1R 2morpholino, 4-(R 6)-piperazino, azetidino, pyrrolidino, piperidino or homopiperidino; Alk : optionally unsaturated, optionally mono- or polysubstituted 1-8C alkyl; Cyc : optionally unsaturated, optionally mono- or polysubstituted 3-8C cycloalkyl; Cyc' : optionally mono- or polysubstituted 3-8C cycloalkyl; Ar : optionally mono- or polysubstituted aryl; Het : optionally mono- or polysubstituted heteroaryl; Q 11-3C alkylene; R 6as for R 1; R 3Alk, Cyc, Ar, Het, -Q 2-Ar, -Q 2-Cyc' or -Q 2-Het ; Q 2optionally unsaturated, optionally substituted 1-4C alkylene; R 4H or optionally protected hydroxy; n : 0 or 1; R 5Cyc', Ar, Het, -CH 2R 12, -(CH 2) 2R 12or -(CH 2) 3R 12; R 12Cyc', Ar or Het. Independent claims are also included for the preparation of (I). ACTIVITY : Analgesic; tranquilizer; antidepressant; anticonvulsant; neuroprotective; nootropic; antiaddictive; antialcoholic; vasotropic; cardiant; hypotensive; hypertensive; auditory; antipruritic; antimigraine; laxative; anorectic; antidiarrheic; immunomodulator; uropathic; relaxant; anesthetic; diuretic. The least polar diastereomer of dimethyl-(1-phenyl-4-(2-p-tolyl-vinyl)-cyclohexylamine hydrochloride (Ia) gave 100% inhibition at a dose of 10 mg/kg i.v. in the mouse writhing test for analgesic activity. MECHANISM OF ACTION : Nociceptin/ORL1 receptor (opioid receptor like-receptor 1) system modulator; ORL1 receptor ligand; mu -opiate receptor ligand. The least polar diastereomer of (Ia) had K ivalues of 200 nM and 42 mu M respectively in ORL1 and mu -receptor binding assays.
机译:1-取代的4-(ω-取代的烷基,烯基或炔基)-环己胺衍生物(I)是新的。式(I)的环己胺衍生物,可选地呈外消旋体,纯立体异构体(特别是对映异构体或非对映异构体)或其各种比例的混合物形式,包括游离碱,游离酸,盐(特别是酸或碱加成盐)或溶剂化物(特别是水合物),是新的。 [图片] -----:可选键; R 1,R 2H,Alk,Cyc,Ar,Het,-Q 1 Ar,-Q 1-Cyc'或-Q 1-Het或NR 1R 2吗啉代,4-(R 6)-哌嗪子基,氮杂环丁烷基,吡咯烷基,哌啶子基或高哌啶子基;烷基:任选地不饱和的,任选地单或多取代的1-8C烷基; Cyc:任选地不饱和的,任选地单或多取代的3-8C环烷基; Cyc':任选地被单或多取代的3-8C环烷基; Ar:任选地单或多取代的芳基; Het:任选地单或多取代的杂芳基; Q 11-3C亚烷基; R 6与R 1相同; R 3Alk,Cyc,Ar,Het,-Q 2-Ar,-Q 2-Cyc'或-Q 2-Het; Q 2任选不饱和,任选取代的1-4C亚烷基; R 4H或任选保护的羟基; n:0或1; R 5Cyc',Ar,Het,-CH 2R 12,-(CH 2)2R 12或-(CH 2)3R 12; R 12Cyc',Ar或Het。独立权利要求也包括用于制备(I)。活动:止痛药;镇定剂抗抑郁药抗惊厥药神经保护促智反吸毒抗酒精促血管坚强低血压高血压听觉止痒抗偏头痛泻药;厌食的止泻药免疫调节剂尿毒症放松剂麻药;利尿的。在小鼠扭体试验中,镇痛活性为10 mg / kg iv时,二甲基-(1-苯基-4-(2-对甲苯基乙烯基)-环己胺盐酸盐(Ia)的极性最小的非对映异构体具有100%的抑制作用作用机理:Nociceptin / ORL1受体(类阿片受体样受体1)系统调节剂; ORL1受体配体;μ阿片受体配体。(Ia)的最小极性非对映异构体分别具有200 nM和42μM的K i值。 ORL1和mu受体结合测定。

著录项

  • 公开/公告号DE10252874A1

    专利类型

  • 公开/公告日2004-09-16

    原文格式PDF

  • 申请/专利权人 GRUENENTHAL GMBH;

    申请/专利号DE2002152874

  • 发明设计人 SUNDERMANN BERND;SCHICK HANS;

    申请日2002-11-12

  • 分类号C07C211/33;A61K31/136;

  • 国家 DE

  • 入库时间 2022-08-21 22:43:43

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号